These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 24478500)
1. Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States. Cohen J; Limbago B; Dumyati G; Holzbauer S; Johnston H; Perlmutter R; Dunn J; Nadle J; Lyons C; Phipps E; Beldavs Z; Clark LA; Lessa FC; J Clin Microbiol; 2014 Feb; 52(2):632-4. PubMed ID: 24478500 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. Lalande V; Barrault L; Wadel S; Eckert C; Petit JC; Barbut F J Clin Microbiol; 2011 Jul; 49(7):2714-6. PubMed ID: 21525213 [TBL] [Abstract][Full Text] [Related]
3. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. Humphries RM; Uslan DZ; Rubin Z J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two commercial molecular assays to a laboratory-developed molecular assay for diagnosis of Clostridium difficile infection. Karre T; Sloan L; Patel R; Mandrekar J; Rosenblatt J J Clin Microbiol; 2011 Feb; 49(2):725-7. PubMed ID: 21123537 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. Le Guern R; Herwegh S; Grandbastien B; Courcol R; Wallet F J Clin Microbiol; 2012 Sep; 50(9):3089-90. PubMed ID: 22760042 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection. Deak E; Miller SA; Humphries RM J Clin Microbiol; 2014 Mar; 52(3):960-3. PubMed ID: 24352999 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. Dalpke AH; Hofko M; Zorn M; Zimmermann S J Clin Microbiol; 2013 Jun; 51(6):1906-8. PubMed ID: 23515539 [TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay. Beck ET; Buchan BW; Riebe KM; Alkins BR; Pancholi P; Granato PA; Ledeboer NA J Clin Microbiol; 2014 Jun; 52(6):1998-2002. PubMed ID: 24671790 [TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of Simplexa universal direct and BD GeneOhm tests for detection of toxigenic Clostridium difficile in stool samples. Nolte FS; Ribeiro-Nesbitt DG J Clin Microbiol; 2014 Jan; 52(1):281-2. PubMed ID: 24197886 [TBL] [Abstract][Full Text] [Related]
11. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. Kok J; Wang Q; Thomas LC; Gilbert GL J Clin Microbiol; 2011 Oct; 49(10):3719-21. PubMed ID: 21849697 [No Abstract] [Full Text] [Related]
12. Automated detection of toxigenic Clostridium difficile in clinical samples: isothermal tcdB amplification coupled to array-based detection. Hicke B; Pasko C; Groves B; Ager E; Corpuz M; Frech G; Munns D; Smith W; Warcup A; Denys G; Ledeboer NA; Lindsey W; Owen C; Rea L; Jenison R J Clin Microbiol; 2012 Aug; 50(8):2681-7. PubMed ID: 22675134 [TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of the Meridian Illumigene™ loop-mediated amplification assay and the Gen Probe ProGastro™ Cd polymerase chain reaction assay for the direct detection of toxigenic Clostridium difficile from fecal samples. Doing KM; Hintz MS Diagn Microbiol Infect Dis; 2012 Jan; 72(1):8-13. PubMed ID: 22015321 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of loop-mediated isothermal amplification assay for detection of Clostridioides difficile infection: A prospective diagnostic performance study. Girão ES; Vásconez Noguera SL; Sanchez Espinoza EP; Pereira Alves Madeira Bezerra CL; Lino FM; Côrtes MF; Alves Dos Santos S; Paranhos-Baccala G; Perdigão Neto LV; Costa SF Anaerobe; 2021 Oct; 71():102410. PubMed ID: 34174401 [TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. Novak-Weekley SM; Marlowe EM; Miller JM; Cumpio J; Nomura JH; Vance PH; Weissfeld A J Clin Microbiol; 2010 Mar; 48(3):889-93. PubMed ID: 20071552 [TBL] [Abstract][Full Text] [Related]
16. Impact of molecular testing on reported Ilieş I; Benneyan JC; Jabur TBC; Baker AW; Anderson DJ Infect Control Hosp Epidemiol; 2020 Mar; 41(3):306-312. PubMed ID: 31852562 [TBL] [Abstract][Full Text] [Related]
17. Diagnosing Clostridioides difficile infections with molecular diagnostics: multicenter evaluation of revogene C. difficile assay. Sambri V; Gateau C; Zannoli S; Dirani G; Couturier J; Op den Buijs I; Roymans R; Hallet E; Arnold M; Zumoberhaus A; Steiner S; van de Bovenkamp J; Altwegg M; Berlinger L; Barbut F; Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1169-1175. PubMed ID: 32062723 [TBL] [Abstract][Full Text] [Related]
18. The diagnostic performance and accuracy of 3 molecular assays for the detection of Clostridium difficile in stool samples, compared with the Xpert® C. difficile assay. Azrad M; Tkhawkho L; Hamo Z; Peretz A J Microbiol Methods; 2020 Jan; 168():105784. PubMed ID: 31758952 [TBL] [Abstract][Full Text] [Related]